[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0114475A - Célula para a produção de composição de anticorpo - Google Patents

Célula para a produção de composição de anticorpo

Info

Publication number
BR0114475A
BR0114475A BR0114475-8A BR0114475A BR0114475A BR 0114475 A BR0114475 A BR 0114475A BR 0114475 A BR0114475 A BR 0114475A BR 0114475 A BR0114475 A BR 0114475A
Authority
BR
Brazil
Prior art keywords
antibody
cell
production
antibody composition
composition
Prior art date
Application number
BR0114475-8A
Other languages
English (en)
Inventor
Yutaka Kanda
Mitsuo Satoh
Kazuyasu Nakamura
Kazuhisa Uchida
Toyohide Shinkawa
Naoko Yamane
Emi Hosaka
Kazuya Yamano
Motoo Yamasaki
Nobuo Hanai
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18788817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0114475(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of BR0114475A publication Critical patent/BR0114475A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"CéLULA PARA A PRODUçãO DE COMPOSIçãO DE ANTICORPO". A presente invenção refere-se a uma célula para a produção de uma molécula de anticorpo tal como anticorpo útil para várias doenças tendo elevada atividade citotóxica mediada por célula dependente de anticorpo, um fragmento do anticorpo e a proteína de fusão tendo a região Fc do anticorpo ou similar, um processo para produzir um composição de anticorpo empregando-se a célula, a composição de anticorpo e uso desta.
BR0114475-8A 2000-10-06 2001-10-05 Célula para a produção de composição de anticorpo BR0114475A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000308526 2000-10-06
PCT/JP2001/008804 WO2002031140A1 (fr) 2000-10-06 2001-10-05 Cellules produisant des compositions d'anticorps

Publications (1)

Publication Number Publication Date
BR0114475A true BR0114475A (pt) 2003-12-23

Family

ID=18788817

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114475-8A BR0114475A (pt) 2000-10-06 2001-10-05 Célula para a produção de composição de anticorpo

Country Status (14)

Country Link
EP (5) EP2314686B2 (pt)
JP (12) JP4290423B2 (pt)
KR (1) KR100877676B1 (pt)
CN (3) CN1894406A (pt)
AU (2) AU9419801A (pt)
BR (1) BR0114475A (pt)
CA (3) CA2953239A1 (pt)
DK (1) DK2314686T4 (pt)
EA (2) EA013224B1 (pt)
ES (3) ES2639222T5 (pt)
HU (2) HU231090B1 (pt)
MX (1) MXPA03002974A (pt)
PL (1) PL218428B1 (pt)
WO (1) WO2002031140A1 (pt)

Families Citing this family (917)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CN1894406A (zh) * 2000-10-06 2007-01-10 协和发酵工业株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1500698B1 (en) * 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
AU2003236019A1 (en) * 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
EP1498491A4 (en) * 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003085118A1 (fr) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
CN104530225A (zh) * 2002-04-09 2015-04-22 协和发酵麒麟株式会社 基因组被修饰的细胞
AU2002338020A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
EP3150630A1 (en) 2002-09-27 2017-04-05 Xencor Inc. Optimized fc variants and methods for their generation
AR042145A1 (es) * 2002-11-27 2005-06-08 Dow Agrociences Llc Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
WO2004081048A1 (ja) 2003-03-13 2004-09-23 Chugai Seiyaku Kabushiki Kaisha 変異受容体に対するアゴニスト活性を有するリガンド
JP2004298180A (ja) * 2003-03-18 2004-10-28 Kyowa Hakko Kogyo Co Ltd ゲノムが改変されたマウス
JP2010220615A (ja) * 2003-03-18 2010-10-07 Kyowa Hakko Kirin Co Ltd ゲノムが改変されたマウス
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
EP2228445A1 (en) * 2003-06-18 2010-09-15 Chugai Seiyaku Kabushiki Kaisha Fucose Transporter
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
EP1652923B1 (en) 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
EP1666501A4 (en) * 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd ANTI-HM1.24 ANTIBODIES WITH MODIFIED SUGAR CHAIN
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
JPWO2005035582A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 Ｃｃｒ４に特異的に結合する抗体組成物
WO2005035577A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. ガングリオシドｇｄ３に特異的に結合する抗体組成物
AU2004279740A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
CA2542121A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Genomically modified cell neutralized to serum-free system
CA2542130A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Cell genomically modified to produce polypeptides with an altered glycosylation pattern
JPWO2005035581A1 (ja) * 2003-10-09 2007-11-22 協和醗酵工業株式会社 ヒトＶＥＧＦ受容体Ｆｌｔ−１に特異的に結合する抗体組成物
AU2004279736A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to ganglioside GM2
US7691810B2 (en) * 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
CN1890262B (zh) * 2003-10-09 2015-01-28 协和发酵麒麟株式会社 抗凝血酶ⅲ组合物的制造方法
AU2004280065A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
FR2861395B1 (fr) 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
JPWO2005053741A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
WO2005053742A1 (ja) * 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US7329353B2 (en) 2004-01-23 2008-02-12 Amgen Inc. LC/MS method of analyzing high molecular weight proteins
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
AU2005256113B2 (en) 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
AU2005272993B2 (en) 2004-07-15 2010-02-11 Xencor, Inc. Optimized Fc variants
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
KR101300546B1 (ko) 2004-08-24 2013-09-02 추가이 세이야쿠 가부시키가이샤 항 글리피칸 3 항체를 이용한 어쥬번트 요법
CN101068836B (zh) * 2004-10-26 2013-08-14 中外制药株式会社 糖链改变的抗磷脂酰肌醇聚糖3抗体
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP2332985A3 (en) 2004-11-12 2012-01-25 Xencor, Inc. Fc variants with altered binding to FcRn
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
WO2006109695A1 (ja) * 2005-04-06 2006-10-19 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換えハプトグロビン組成物
WO2006109698A1 (ja) * 2005-04-06 2006-10-19 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換えエリスロポイエチン組成物
WO2006109696A1 (ja) * 2005-04-06 2006-10-19 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換え卵胞刺激ホルモン組成物
WO2012018687A1 (en) 2010-08-02 2012-02-09 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006121852A2 (en) 2005-05-05 2006-11-16 Duke University Anti-cd19 antibody therapy for autoimmune disease
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
WO2008020586A1 (en) 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
RS53263B (en) 2006-08-14 2014-08-29 Xencor Inc. CD19 OPTIMIZED ANTIBODY
JP5562031B2 (ja) 2006-09-18 2014-07-30 ゼンコー・インコーポレイテッド Ｈｍ１．２４を標的とする最適化抗体
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3040347A3 (en) 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
AU2007332473B2 (en) 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
WO2008077545A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Selection method
EP2123676A4 (en) 2007-01-05 2011-01-05 Univ Tokyo DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-PRG-3 ANTIBODIES
EP2119780B1 (en) 2007-01-24 2015-03-25 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
JPWO2008090960A1 (ja) 2007-01-24 2010-05-20 協和発酵キリン株式会社 ガングリオシドｇｍ２に特異的に結合する遺伝子組換え抗体組成物
KR20090114443A (ko) 2007-02-09 2009-11-03 제넨테크, 인크. 항-Ｒｏｂｏ４ 항체 및 그의 용도
EP2447719B1 (en) 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteins
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
JP5311060B2 (ja) 2007-03-08 2013-10-09 カロバイオス ファーマシューティカルズ インコーポレイティッド 固形腫瘍の治療のためのＥｐｈＡ３抗体
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
MX2009011996A (es) 2007-05-07 2010-04-21 Medimmune Llc Anticuerpos anti-coestimulador inducible y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunologica.
US20100291073A1 (en) 2007-05-14 2010-11-18 Medimmune, Llc Methods of reducing eosinophil levels
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2009001840A1 (ja) 2007-06-25 2008-12-31 Forerunner Pharma Research Co., Ltd. ADCC活性又はCDC活性を有する抗Prominin-1抗体
KR101510778B1 (ko) * 2007-07-12 2015-04-10 상가모 바이오사이언스 인코포레이티드 알파 1,6 당전이효소(ｆｕｔ8) 유전자 발현을 비활성화시키기 위한 방법 및 조성물
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
KR101561416B1 (ko) 2007-08-30 2015-10-16 다이이찌 산쿄 가부시키가이샤 항ｅｐｈａ２ 항체
MX342551B (es) 2007-09-26 2016-10-04 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
CN102112492B (zh) 2007-11-14 2015-02-25 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2604628A3 (en) 2007-12-21 2013-08-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4R) - 173
EP3575317A1 (en) 2007-12-26 2019-12-04 Xencor, Inc. Fc variants with altered binding to fcrn
US9274119B2 (en) 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
KR101614494B1 (ko) 2008-04-02 2016-04-22 마크로제닉스, 인크. Ｂｃｒ-복합체-특이적 항체 및 그것의 사용 방법
SI2247304T1 (sl) 2008-04-02 2016-11-30 Macrogenics, Inc. Protitelesa, specifična za HER2/neu, in postopki za njihovo uporabo
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
TR201808535T4 (tr) 2008-04-11 2018-07-23 Chugai Pharmaceutical Co Ltd İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
WO2009131239A1 (ja) 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
EP2311493A4 (en) * 2008-05-20 2012-09-26 Kaneka Corp CYTOTOXIC COMPOSITION
WO2009147781A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
ES2675730T3 (es) 2008-06-04 2018-07-12 Macrogenics, Inc. Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
AU2009267294B2 (en) 2008-06-30 2014-06-26 Kyowa Kirin Co., Ltd. Anti-CD27 antibody
CN103172735B (zh) 2008-07-17 2014-12-10 协和发酵麒麟株式会社 抗-系统asc氨基酸转运蛋白2(asct2)抗体
JP5662149B2 (ja) 2008-08-13 2015-01-28 協和発酵キリン株式会社 遺伝子組換えプロテインｓ組成物
PL3190128T3 (pl) 2008-09-17 2019-06-28 Xencor, Inc. Kompozycje i sposoby leczenia zaburzeń, w których pośredniczy IgE
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
US8084222B2 (en) 2008-09-26 2011-12-27 Eureka Therapeutics, Inc. Methods for generating host cells
MX2011004001A (es) 2008-10-14 2011-05-19 Genentech Inc Variantes de inmunoglobulinas y sus usos.
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
US8846870B2 (en) 2008-12-22 2014-09-30 Chugai Seiyaku Kabushiki Kaisha Anti-HS6ST2 antibodies and uses thereof
CA2746330C (en) 2008-12-23 2017-08-29 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
EP2385114A4 (en) 2008-12-25 2012-08-08 Univ Tokyo CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
MX2011006908A (es) 2008-12-26 2011-10-06 Univ Tokio Diagnosis y tratamiento del cancer utilizando el anticuerpo anti-lgr7.
PT2374883T (pt) 2008-12-26 2016-10-20 Kyowa Hakko Kirin Co Ltd Anticorpo anti-cd4
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
CA2753995A1 (en) 2009-03-06 2010-09-10 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
PE20120539A1 (es) 2009-03-20 2012-05-12 Genentech Inc Anticuerpos anti-her biespecifico
MA33210B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Nouveaux anticorps anti-a5b1 et leurs utilisations
BRPI1010297A2 (pt) 2009-04-07 2017-06-06 Roche Glycart Ag anticorpos biespecíficos trivalentes.
MY152033A (en) 2009-04-09 2014-08-15 Daiichi Sankyo Co Ltd Anti-siglec-15 antibody
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
ES2829423T3 (es) 2009-04-20 2021-05-31 Kyowa Kirin Co Ltd Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo
CN104558179A (zh) 2009-04-27 2015-04-29 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗IL-3Rα抗体
SG176074A1 (en) 2009-05-15 2011-12-29 Chugai Pharmaceutical Co Ltd Anti-axl antibody
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
ES2661074T3 (es) 2009-06-02 2018-03-27 Regeneron Pharmaceuticals, Inc. Células deficientes de fucosilación
EP2441831B9 (en) 2009-06-11 2019-03-06 Inter-University Research Institute Corporation Research Organization of Information and Systems Process for production of protein
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102802661B (zh) 2009-06-22 2016-01-13 米迪缪尼有限公司 用于位点特异性偶联的工程改造的Fc区
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CN102597233B (zh) 2009-08-07 2014-10-29 协和发酵麒麟株式会社 人源化抗淀粉样-b寡聚体抗体
ES2661601T3 (es) 2009-08-07 2018-04-02 Kyowa Hakko Kirin Co., Ltd. Anticuerpo humanizado antioligómero de amiloide-beta
CN102574917A (zh) 2009-08-17 2012-07-11 株式会社未来创药研究所 含有抗hb-egf抗体作为有效成分的药物组合物
EP2473522B1 (en) 2009-09-02 2016-08-17 Genentech, Inc. Mutant smoothened and methods of using the same
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011030841A1 (ja) 2009-09-10 2011-03-17 協和発酵キリン株式会社 ヒトｃｃケモカイン受容体４（ｃｃｒ４）に特異的に結合する抗体組成物を含む医薬
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2010297580B2 (en) * 2009-09-22 2014-07-31 Probiogen Ag Process for producing molecules containing specialized glycan structures
US8697073B2 (en) 2009-09-30 2014-04-15 Fujifilm Ri Pharma Co., Ltd. Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
DK2486141T3 (en) 2009-10-07 2018-04-23 Macrogenics Inc FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
RU2559542C2 (ru) 2009-12-23 2015-08-10 Дженентек, Инк. Антитела против bv8 и их применение
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
HUE056313T2 (hu) 2010-01-29 2022-02-28 Chugai Pharmaceutical Co Ltd Anti-DLL3 antitest
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
KR101900110B1 (ko) 2010-02-10 2018-09-18 후지필름 알아이 파르마 가부시키가이샤 방사성 금속 표지 항카드헤린 항체
RU2573994C2 (ru) 2010-02-10 2016-01-27 Иммьюноджен, Инк Антитела против cd20 и их применение
WO2011103242A1 (en) 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011105573A1 (ja) 2010-02-26 2011-09-01 株式会社未来創薬研究所 抗icam3抗体およびその用途
EP2543727B1 (en) 2010-03-02 2016-08-31 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
WO2011109400A2 (en) 2010-03-04 2011-09-09 Macrogenics,Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8846041B2 (en) 2010-03-24 2014-09-30 Genentech, Inc. Anti-LRP6 antibodies
EP2554669B1 (en) 2010-03-26 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Novel antibody having modification site introduced therein, and antibody fragment
WO2011120134A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
US9169329B2 (en) 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
TR201807750T4 (tr) 2010-06-11 2018-06-21 Kyowa Hakko Kirin Co Ltd Anti-TIM-3 antikoru.
BR112012027995A2 (pt) 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
DK3323830T3 (da) 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
WO2012005076A1 (ja) 2010-07-08 2012-01-12 本田技研工業株式会社 高周波加熱用コイル
EP2591004A1 (en) 2010-07-09 2013-05-15 F.Hoffmann-La Roche Ag Anti-neuropilin antibodies and methods of use
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
KR20130045914A (ko) 2010-08-03 2013-05-06 에프. 호프만-라 로슈 아게 만성 림프구성 백혈병(cll) 생체지표
WO2012017003A1 (en) 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
BR112013002444A2 (pt) 2010-08-13 2016-05-24 Roche Glycart Ag anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
CA2806021C (en) 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
WO2012025536A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
KR20140018837A (ko) 2010-08-27 2014-02-13 스템 센트알엑스 인코포레이티드 노텀 단백질 조절 인자 및 사용 방법
CN103221825A (zh) 2010-08-31 2013-07-24 基因泰克公司 生物标志物和治疗方法
AU2011295715B9 (en) 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
EP2623119B1 (en) 2010-09-30 2017-06-14 Riken Drug used in glioma treatment method, glioma examination method, method of delivering a desired material to a glioma
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
JP5918143B2 (ja) 2010-10-29 2016-05-18 第一三共株式会社 新規抗ｄｒ５抗体
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
KR102099580B1 (ko) 2010-11-17 2020-04-10 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
NZ728016A (en) 2010-12-08 2020-06-26 Abbvie Stemcentrx Llc Novel modulators and methods of use
RU2598255C2 (ru) 2010-12-15 2016-09-20 Интер-Юниверсити Рисерч Инститьют Корпорейшн Рисерч Организейшн Оф Информейшн Энд Системз Способ получения белка
CA2821888C (en) 2010-12-15 2019-03-26 Kyowa Hakko Kirin Co., Ltd. Method for producing proteins
JP6005657B2 (ja) 2010-12-16 2016-10-12 ジェネンテック， インコーポレイテッド Ｔｈ２阻害に関連する診断及び治療
MA34881B1 (fr) 2010-12-20 2014-02-01 Genentech Inc Anticorps et immunoconjugués anti-mésothéline
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
JP5883396B2 (ja) 2010-12-27 2016-03-15 国立大学法人名古屋大学 受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
FR2971250A1 (fr) 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2681239B8 (en) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
MX346663B (es) * 2011-03-06 2017-03-27 Merck Serono Sa Lineas de celulas de bajo nivel de fucosa y usos de las mismas.
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
BR112013024717A2 (pt) 2011-04-07 2017-08-08 Genentech Inc anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
WO2012144208A1 (ja) 2011-04-18 2012-10-26 国立大学法人東京大学 抗itm2a抗体を用いる癌の診断および治療
JP5588086B2 (ja) 2011-04-19 2014-09-10 メリマック ファーマシューティカルズ インコーポレーティッド 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体
KR102030987B1 (ko) 2011-04-25 2019-11-11 다이이찌 산쿄 가부시키가이샤 항 ｂ７-ｈ３항체
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
RU2638806C2 (ru) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms способ мониторинга множественных реакций для выявления терапевтических антител в образцах животных с помощью каркасных сигнатурных пептидов
RS56090B1 (sr) 2011-05-16 2017-10-31 Hoffmann La Roche Fgfr1 agonisti i načini primene
NZ618016A (en) 2011-05-21 2015-05-29 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
KR20140033152A (ko) 2011-06-20 2014-03-17 교와 핫꼬 기린 가부시키가이샤 항erbB3 항체
CN103649125A (zh) 2011-06-22 2014-03-19 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
WO2013001369A2 (en) 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
RU2014109093A (ru) 2011-08-17 2015-09-27 Дженентек, Инк. Антитела против нейрегулина и их применение
JP2014534806A (ja) 2011-08-23 2014-12-25 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
BR112014005720A2 (pt) 2011-09-15 2017-12-12 Genentech Inc método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
CN103930111A (zh) 2011-09-19 2014-07-16 霍夫曼-拉罗奇有限公司 包含c-met拮抗剂和b-raf拮抗剂的组合治疗
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
KR102492584B1 (ko) 2011-09-30 2023-01-27 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
MX2014004074A (es) 2011-10-05 2014-06-05 Genentech Inc Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
CA3182462A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9738727B2 (en) 2011-10-14 2017-08-22 Genentech, Inc. Anti-HtrA1 antibodies and methods of use
JP6254087B2 (ja) 2011-10-15 2017-12-27 ジェネンテック， インコーポレイテッド 癌を治療するためのｓｃｄ１アンタゴニスト
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
IN2014CN03062A (pt) 2011-10-28 2015-07-31 Hoffmann La Roche
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
HUE056462T2 (hu) 2011-11-04 2022-02-28 Zymeworks Inc Stabil heterodimer antestest tervezés mutációkkal az FC domainben
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
WO2013087789A1 (en) 2011-12-13 2013-06-20 Glykos Finland Ltd. Antibody isoform arrays and methods thereof
SG10201700169PA (en) 2011-12-22 2017-02-27 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
SG11201403223PA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
BR112014013035A2 (pt) 2011-12-22 2018-10-09 Hoffmann La Roche métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
IN2014DN05885A (pt) 2012-01-18 2015-06-05 Hoffmann La Roche
MX2014008699A (es) 2012-01-18 2014-11-21 Genentech Inc Metodos para utilizar moduladores de fgf19.
CA2863066A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
CN113527469A (zh) 2012-02-09 2021-10-22 中外制药株式会社 抗体的Fc区变异体
EP2812350B1 (en) 2012-02-11 2019-04-03 F.Hoffmann-La Roche Ag R-spondin translocations and methods using the same
PL2814587T3 (pl) 2012-02-15 2018-10-31 F.Hoffmann-La Roche Ag Chromatografia powinowactwa oparta na receptorze Fc
US9228006B2 (en) 2012-03-16 2016-01-05 University Health Network Methods and compositions for modulating Toso activity
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
TW201343672A (zh) 2012-03-30 2013-11-01 Daiichi Sankyo Co Ltd Ｃｄｒ經修飾之抗ｓｉｇｌｅｃ－１５抗體
RU2014143770A (ru) 2012-03-30 2016-05-27 Дайити Санкио Компани, Лимитед Новое антитело против siglec-15
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
JP6188681B2 (ja) 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
WO2013155346A1 (en) 2012-04-11 2013-10-17 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
CN104768973B (zh) 2012-04-27 2019-01-22 第一三共株式会社 抗robo4抗体
MX2014012889A (es) 2012-05-01 2014-11-14 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17.
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
EP2848633B1 (en) 2012-05-11 2019-02-06 Microbial Chemistry Research Foundation Anti-cxadr antibody
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
RU2625771C2 (ru) 2012-05-23 2017-07-18 Дженентек, Инк. Способ отбора терапевтических средств
EP2857420B1 (en) 2012-05-30 2020-09-23 Chugai Seiyaku Kabushiki Kaisha Target-tissue-specific antigen-binding molecule
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
AR091462A1 (es) 2012-06-15 2015-02-04 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CN104411720B (zh) 2012-07-02 2018-05-11 协和发酵麒麟株式会社 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂
BR112014030844A2 (pt) 2012-07-04 2019-10-15 Hoffmann La Roche anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
KR20150023938A (ko) 2012-07-04 2015-03-05 에프. 호프만-라 로슈 아게 항-테오필린 항체 및 이의 사용 방법
CN104428006B (zh) 2012-07-04 2017-09-08 弗·哈夫曼-拉罗切有限公司 共价连接的抗原‑抗体缀合物
KR20150030693A (ko) 2012-07-05 2015-03-20 제넨테크, 인크. 발현 및 분비 시스템
AU2013285970B2 (en) 2012-07-06 2017-11-30 Kyowa Kirin Co., Ltd. Therapeutic method and remedy for HTLV-1-associated myelopathy patients
BR112015000437A2 (pt) 2012-07-09 2017-06-27 Genentech Inc imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
EA201590174A1 (ru) 2012-07-09 2015-09-30 Дженентек, Инк. Иммуноконъюгаты, содержащие анти-cd22 антитела
WO2014011521A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti - cd79b antibodies
AU2013288931A1 (en) 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti-CD22 antibodies
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
MX369550B (es) 2012-09-27 2019-11-12 Chugai Pharmaceutical Co Ltd Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo.
JP6273205B2 (ja) 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
KR102237639B1 (ko) 2012-10-11 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
MA38165A1 (fr) 2012-11-08 2018-07-31 Hoffmann La Roche Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
EP3461501A1 (en) 2012-11-13 2019-04-03 F. Hoffmann-La Roche AG Anti-hemagglutinin antibodies and methods of use
WO2014088040A1 (ja) 2012-12-06 2014-06-12 国立大学法人 金沢大学 中皮腫の治療方法
CA2893378A1 (en) 2012-12-07 2014-06-12 Kyowa Hakko Kirin Co., Ltd. Anti-folr1 antibody
PL2935328T3 (pl) 2012-12-21 2019-02-28 Hoffmann La Roche Połączone wiązaniem dwusiarczkowym wielowartościowe białka wielofunkcyjne zawierające MHC klasy I
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP4119947A1 (en) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
CA2896955C (en) 2013-01-10 2023-10-31 Genmab B.V. Human igg1 fc region variants and uses thereof
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
DK2943511T3 (da) 2013-01-14 2019-10-21 Xencor Inc Nye heterodimeriske proteiner
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
US9932396B2 (en) 2013-02-08 2018-04-03 Medical & Biological Laboratories Co., Ltd. Antibody against human NRG1 protein
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
JP2016512489A (ja) 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
BR112015021462A2 (pt) 2013-03-06 2017-10-10 Adimab Llc anticorpos biespecíficos anti-c-met tandem fc
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
AU2014239903A1 (en) 2013-03-14 2015-09-17 Genentech, Inc. Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
MX2015010777A (es) 2013-03-14 2016-04-25 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4.
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US20140328849A1 (en) 2013-03-15 2014-11-06 Genentech, Inc. Anti-crth2 antibodies and methods of use
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
TW201511770A (zh) 2013-03-15 2015-04-01 Genentech Inc 診斷及治療肝癌之組合物及方法
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
DK3587448T3 (da) 2013-03-15 2021-08-09 Xencor Inc Heterodimere proteiner
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
KR102389677B1 (ko) 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014174596A1 (ja) 2013-04-23 2014-10-30 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
CA2908653A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
KR102266819B1 (ko) 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
TWI573805B (zh) 2013-05-20 2017-03-11 建南德克公司 抗轉鐵蛋白受體抗體及其使用方法
EP3004161B1 (en) 2013-05-31 2019-10-02 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
MX369022B (es) 2013-05-31 2019-10-25 Genentech Inc Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
CA2916362A1 (en) * 2013-06-24 2014-12-31 Masami Suzuki Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
HUE058243T2 (hu) 2013-08-01 2022-07-28 Five Prime Therapeutics Inc Afukozilált, FGFR2IIIB elleni antitestek
BR112016004450A2 (pt) 2013-09-17 2017-10-17 Genentech Inc métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
EP3835422A1 (en) 2013-09-30 2021-06-16 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
WO2015053407A1 (ja) 2013-10-08 2015-04-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
CN105745224B (zh) 2013-10-11 2019-11-05 牛津生物疗法有限公司 用于治疗癌症的针对ly75的偶联抗体
CA2925393C (en) 2013-10-11 2023-03-07 Dimiter Dimitrov Tem8 antibodies and their use
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
JP2016537965A (ja) 2013-10-11 2016-12-08 ジェネンテック， インコーポレイテッド Ｎｓｐ４阻害剤及び使用方法
EP3057615B1 (en) 2013-10-18 2021-02-24 F.Hoffmann-La Roche Ag Anti-rspo antibodies and methods of use
MX2016005159A (es) 2013-10-23 2016-07-05 Genentech Inc Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
US20160264648A1 (en) 2013-11-06 2016-09-15 Osaka University Antibody having broad neutralization activity against group 1 influenza a viruses
MX2016005631A (es) 2013-11-21 2016-07-14 Hoffmann La Roche Anticuerpos anti-alfa-sinucleina y metodos de uso.
SG11201604495PA (en) 2013-12-04 2016-07-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
CN110590950A (zh) 2013-12-13 2019-12-20 基因泰克公司 抗cd33抗体和免疫缀合物
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
NZ721309A (en) 2013-12-17 2019-11-29 Genentech Inc Anti-cd3 antibodies and methods of use
BR112016013741A2 (pt) 2013-12-17 2017-10-03 Genentech Inc Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
KR102447878B1 (ko) 2013-12-17 2022-09-26 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
NZ721213A (en) 2013-12-25 2022-12-23 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
EP4223874A3 (en) 2013-12-26 2023-09-27 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
ES2756175T3 (es) 2013-12-27 2020-04-27 Chugai Pharmaceutical Co Ltd Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos
MX2016008187A (es) 2014-01-03 2016-09-29 Hoffmann La Roche Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica.
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
RU2682754C2 (ru) 2014-01-03 2019-03-21 Ф. Хоффманн-Ля Рош Аг Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью
CA2930154A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CA2932547C (en) 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
CA2931986A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
EP3096797A1 (en) 2014-01-24 2016-11-30 F. Hoffmann-La Roche AG Methods of using anti-steap1 antibodies and immunoconjugates
CN105829346B (zh) 2014-01-31 2019-08-23 第一三共株式会社 抗her2抗体－药物偶联物
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
TWI769970B (zh) 2014-02-08 2022-07-11 美商建南德克公司 治療阿茲海默症之方法
KR20240094017A (ko) 2014-02-08 2024-06-24 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
SG10201808259TA (en) 2014-02-12 2018-10-30 Genentech Inc Anti-jagged1 antibodies and methods of use
SG11201606870XA (en) 2014-02-21 2016-09-29 Genentech Inc Anti-il-13/il-17 bispecific antibodies and uses thereof
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
KR102561695B1 (ko) 2014-03-14 2023-07-28 제넨테크, 인크. 이형 폴리펩티드의 분비를 위한 방법 및 조성물
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
KR20160137599A (ko) 2014-03-24 2016-11-30 제넨테크, 인크. C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
AU2015237184B2 (en) 2014-03-28 2020-11-26 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
HUE046767T2 (hu) 2014-03-31 2020-03-30 Hoffmann La Roche Anti-OX40 antitestek és alkalmazási eljárások
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
EP3145952A2 (en) 2014-05-22 2017-03-29 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
BR112016025040A2 (pt) 2014-05-23 2018-02-20 Genentech Inc métodos para determinar a expressão de biomarcador mit, para tratar câncer, para identificar um indivíduo com câncer, para predizer se um indivíduo com câncer tem mais ou menos probabilidade de responder efetivamente ao tratamento, para inibir a proliferação de uma célula e para tratar nccrcc em um indivíduo
SG11201609487QA (en) 2014-06-03 2016-12-29 Xbiotech Inc Compositions and methods for treating and preventing staphylococcus aureus infections
JP2017526618A (ja) 2014-06-11 2017-09-14 ジェネンテック， インコーポレイテッド 抗ＬｇＲ５抗体及びその使用
EP3154589A1 (en) 2014-06-13 2017-04-19 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2015197736A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
WO2016007235A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
AU2015292326A1 (en) 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CN107074975A (zh) 2014-08-28 2017-08-18 生物蛋白有限公司 用于修饰的t细胞的条件活性嵌合抗原受体
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
WO2016040723A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-her2 antibodies and immunoconjugates
CN106804108B (zh) 2014-09-12 2021-08-10 基因泰克公司 抗-b7-h4抗体及免疫缀合物
EP3693391B1 (en) 2014-09-12 2024-08-21 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
MX2017003472A (es) 2014-09-17 2017-10-31 Genentech Inc Inmunoconjugados que comprenden anticuerpos anti-her2.
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
EP3215637B1 (en) 2014-11-03 2019-07-03 F. Hoffmann-La Roche AG Methods and biomarkers for predicting efficacy and valuation of an ox40 agonist treatment
US20160161485A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
CA2960569A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-Laroche Ag Fc-region variants with modified fcrn- and protein a-binding properties
LT3215528T (lt) 2014-11-06 2019-10-25 Hoffmann La Roche Fc srities variantai su modifikuota fcrn jungtimi ir naudojimo būdai
EP3217787B1 (en) 2014-11-10 2019-04-17 F.Hoffmann-La Roche Ag Animal model for nephropathy and agents for treating the same
SG11201703767XA (en) 2014-11-10 2017-06-29 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
EP3875481A1 (en) 2014-11-14 2021-09-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
US10882920B2 (en) 2014-11-19 2021-01-05 Genentech, Inc. Antibodies against BACE1 and use thereof for neural disease immunotherapy
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
CN107250158B (zh) 2014-11-19 2022-03-25 基因泰克公司 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
ES2926673T3 (es) 2014-11-20 2022-10-27 Hoffmann La Roche Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1
PE20171103A1 (es) 2014-11-26 2017-08-07 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
NZ732144A (en) 2014-11-26 2020-04-24 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
KR20170086542A (ko) 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코쿠스 아우레우스 항체 리파마이신 콘주게이트 및 그것의 용도
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
MX2017007055A (es) 2014-12-03 2017-11-08 Genentech Inc Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
PT3227336T (pt) 2014-12-05 2019-09-09 Hoffmann La Roche Anticorpos anti-cd79b e métodos de utilização
EP3230317A2 (en) 2014-12-10 2017-10-18 F. Hoffmann-La Roche AG Blood brain barrier receptor antibodies and methods of use
AU2015365168B2 (en) 2014-12-19 2021-08-05 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
EP3233921B1 (en) 2014-12-19 2021-09-29 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
MX2017009254A (es) 2015-01-16 2017-10-12 Juno Therapeutics Inc Anticuerpos y receptores de antigeno quimerico especificos para ror1.
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
CN107636170A (zh) 2015-02-04 2018-01-26 健泰科生物技术公司 突变型Smoothened及其使用方法
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
WO2016130539A2 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CA2977285A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3271389B8 (en) 2015-03-20 2020-04-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to gp120 and their use
CN107530428B (zh) 2015-03-23 2022-05-13 震动疗法股份有限公司 Icos的抗体
US10472412B2 (en) 2015-03-25 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific multivalent fusion proteins
SG10201913158PA (en) 2015-04-03 2020-02-27 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
ES2881694T3 (es) 2015-04-24 2021-11-30 Hoffmann La Roche Procedimientos de identificación de bacterias que comprenden polipéptidos de unión
SI3290441T1 (sl) 2015-04-28 2020-03-31 Mitsubishi Tanabe Pharma Corporation RGMA-vezavni protein in njegova uporaba
CN107709363A (zh) 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
MX2017014188A (es) 2015-05-07 2018-04-10 Agenus Inc Anticuerpos anti-ox40 y metodos para su uso.
CN107592812A (zh) 2015-05-11 2018-01-16 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
SI3294770T2 (sl) 2015-05-12 2024-06-28 F. Hoffmann-La Roche Ag Terapevtski in diagnostični postopki za raka
US11267899B2 (en) * 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
CN107771182A (zh) 2015-05-29 2018-03-06 豪夫迈·罗氏有限公司 人源化抗埃博拉病毒糖蛋白抗体和使用方法
IL294138A (en) 2015-05-29 2022-08-01 Genentech Inc Therapeutic and diagnostic methods for cancer
WO2016196679A1 (en) 2015-06-02 2016-12-08 Genentech, Inc. Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
EP3303399A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies
TW201709934A (zh) 2015-06-15 2017-03-16 建南德克公司 抗體及免疫結合物
CN107849145B (zh) 2015-06-16 2021-10-26 基因泰克公司 抗cd3抗体及其使用方法
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
EP4299073A3 (en) 2015-06-16 2024-03-27 F. Hoffmann-La Roche AG Humanized and affinity matured antibodies to fcrh5 and methods of use
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
JP2018524312A (ja) 2015-06-17 2018-08-30 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体及び使用方法
CR20210429A (es) 2015-06-24 2021-09-24 Hoffmann La Roche ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
EP3978525A1 (en) 2015-06-29 2022-04-06 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
AU2016285596A1 (en) 2015-06-29 2018-01-18 Genentech, Inc. Type II anti-CD20 antibody for use in organ transplantation
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
RS60030B1 (sr) 2015-08-03 2020-04-30 Engmab Sarl Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma)
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP6914919B2 (ja) 2015-08-28 2021-08-04 ジェネンテック， インコーポレイテッド 抗ヒプシン抗体及びその使用
PE20181336A1 (es) 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
WO2017050729A1 (en) 2015-09-22 2017-03-30 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
UA125432C2 (uk) 2015-09-23 2022-03-09 Дженентек, Інк. Оптимізовані варіанти анти-vegf антитіл
CN108289954B (zh) 2015-09-24 2022-05-31 阿布维特罗有限责任公司 Hiv抗体组合物和使用方法
SI3354729T1 (sl) 2015-09-24 2024-05-31 Daiichi Sankyo Company, Limited Protitelesa anti-garp
WO2017053748A2 (en) 2015-09-25 2017-03-30 Genentech, Inc. Anti-tigit antibodies and methods of use
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
MA43023A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
EP3359570A1 (en) 2015-10-07 2018-08-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
CA2998208A1 (en) 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
AU2016344665C1 (en) 2015-10-29 2023-07-27 F. Hoffmann-La Roche Ag Anti-variant Fc-region antibodies and methods of use
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
MX2018004509A (es) 2015-10-30 2018-08-01 Genentech Inc Anticuerpos anti-htra1 y metodos de uso de los mismos.
WO2017079479A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Neutralizing antibodies to hiv-1 gp41 and their use
CN118725134A (zh) 2015-11-08 2024-10-01 豪夫迈·罗氏有限公司 筛选多特异性抗体的方法
CA3004794A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
AU2016365742A1 (en) 2015-12-07 2018-06-21 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
AU2016372930B2 (en) 2015-12-18 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
WO2017127764A1 (en) 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
KR20180119632A (ko) 2016-02-29 2018-11-02 제넨테크, 인크. 암에 대한 치료 및 진단 방법
BR112018067923A2 (pt) 2016-03-15 2019-02-05 Chugai Pharmaceutical Co Ltd métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
WO2017168726A1 (ja) * 2016-03-31 2017-10-05 国立大学法人東北大学 がん微小環境を標的とした抗ポドカリキシン抗体
EP3443004A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3 antibodies and methods of use
AU2017248644B2 (en) 2016-04-15 2019-10-31 Bioatla, Llc Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
CN109154027A (zh) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 用于监测和治疗癌症的方法
KR20190003958A (ko) 2016-04-15 2019-01-10 제넨테크, 인크. 암의 치료 및 모니터링 방법
RU2018141360A (ru) 2016-05-02 2020-06-03 Ф. Хоффманн-Ля Рош Аг Contorsbody - одноцепочечный связывающий мишень агент
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
MX2018013306A (es) 2016-05-13 2019-01-30 Bioatla Llc Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
CN109475618A (zh) 2016-05-18 2019-03-15 根马布私人有限公司 抗体及其在治疗传染病中的使用方法
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
EP4371570A3 (en) 2016-06-08 2024-07-17 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
EP3468586B1 (en) 2016-06-14 2024-08-07 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
JP7133477B2 (ja) 2016-06-24 2022-09-08 ジェネンテック， インコーポレイテッド 抗ポリユビキチン多重特異性抗体
AU2017290086A1 (en) 2016-06-28 2019-01-24 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
BR112019000544A2 (pt) 2016-07-15 2019-04-24 Takeda Pharmaceutical Company Limited métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP7062640B2 (ja) 2016-07-29 2022-05-06 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体
CA3027018A1 (en) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3510046A4 (en) 2016-09-07 2020-05-06 The Regents of the University of California ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
WO2018053032A1 (en) 2016-09-13 2018-03-22 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN109689682B (zh) 2016-09-19 2022-11-29 豪夫迈·罗氏有限公司 基于补体因子的亲和层析
JP6995844B2 (ja) 2016-09-23 2022-02-04 ジェネンテック， インコーポレイテッド アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
KR20190062505A (ko) 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
TWI775781B (zh) 2016-10-06 2022-09-01 美商建南德克公司 癌症之治療性及診斷性方法
BR112019005247A2 (pt) 2016-10-07 2019-06-04 Daiichi Sankyo Co Ltd terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
US10550185B2 (en) 2016-10-14 2020-02-04 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
KR20190070977A (ko) 2016-11-01 2019-06-21 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
PT3535298T (pt) 2016-11-02 2021-11-25 Jounce Therapeutics Inc Anticorpos para pd-1 e seu uso
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2018091724A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
TW201825119A (zh) 2016-11-30 2018-07-16 日商協和醱酵麒麟有限公司 使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
CN110366562A (zh) 2016-12-12 2019-10-22 豪夫迈·罗氏有限公司 使用抗pd-l1抗体和抗雄激素治疗癌症的方法
KR20190095280A (ko) 2016-12-12 2019-08-14 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합
AU2017379382A1 (en) 2016-12-22 2019-07-11 Daiichi Sankyo Company, Limited Anti-CD3 Antibody and Molecules Comprising the Antibody
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CN118638228A (zh) 2016-12-26 2024-09-13 协和麒麟株式会社 与髓鞘少突胶质细胞糖蛋白结合的抗体
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
EP3523332B1 (en) 2017-01-06 2021-12-29 Eutilex Co., Ltd. Anti-human 4-1 bb antibodies and use thereof
EP3568468A4 (en) 2017-01-12 2020-12-30 Eureka Therapeutics, Inc. RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
CA3050668C (en) 2017-01-17 2023-08-15 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
US11208491B2 (en) 2017-01-24 2021-12-28 Kyowa Kirin Co., Ltd. Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibody
SG10201912368XA (en) 2017-02-07 2020-02-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
WO2018146317A1 (en) 2017-02-10 2018-08-16 Genmab B.V. Polypeptide variants and uses thereof
SG11201907242TA (en) 2017-02-10 2019-09-27 Eutilex Co Ltd IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
AR110873A1 (es) 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
EP3580235B1 (en) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20200061031A1 (en) 2017-02-28 2020-02-27 Kinki University Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
ES2953595T3 (es) 2017-03-01 2023-11-14 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
WO2018159845A1 (ja) 2017-03-02 2018-09-07 学校法人 聖マリアンナ医科大学 低用量抗ｃｃｒ４抗体を用いたｈｔｌｖ－１関連脊髄症の予防または治療剤
BR112019019706A2 (pt) 2017-03-22 2020-04-28 Genentech Inc conjugado de anticorpo, anticorpo, composição farmacêutica, métodos para reduzir ou inibir angiogênese e para tratar um distúrbio ocular
TW202400231A (zh) 2017-03-28 2024-01-01 美商建南德克公司 治療神經退化性疾病之方法
EP3616720B1 (en) 2017-03-29 2021-02-17 Shionogi&Co., Ltd. Pharmaceutical composition for cancer treatment
CN110475789B (zh) 2017-03-30 2023-12-05 国立大学法人东北大学 抗平足蛋白抗体
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018191660A1 (en) 2017-04-14 2018-10-18 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN110536691A (zh) 2017-04-21 2019-12-03 豪夫迈·罗氏有限公司 Klk5拮抗剂治疗疾病的用途
KR20240067275A (ko) 2017-04-26 2024-05-16 유레카 쎄라퓨틱스, 인코포레이티드 글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
JP2020517695A (ja) 2017-04-27 2020-06-18 テサロ， インコーポレイテッド リンパ球活性化遺伝子−３（ｌａｇ−３）に対する抗体薬およびそれらの使用
US11116835B2 (en) 2017-05-10 2021-09-14 Fred Hutchinson Cancer Research Center Epstein Barr virus antibodies, vaccines, and uses of the same
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
CN118416216A (zh) 2017-05-16 2024-08-02 戊瑞治疗有限公司 癌症治疗中抗fgfr2抗体与化学治疗剂的组合
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
JP7197865B2 (ja) 2017-07-18 2022-12-28 協和キリン株式会社 抗ヒトｃｃｒ１モノクローナル抗体
MX2020000604A (es) 2017-07-21 2020-09-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
WO2019023347A1 (en) 2017-07-26 2019-01-31 Forty Seven, Inc. ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS
US11661451B2 (en) 2017-07-27 2023-05-30 Daiichi Sankyo Company, Limited Anti-CD147 antibody
JP7204651B2 (ja) 2017-08-23 2023-01-16 第一三共株式会社 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法
CR20200138A (es) 2017-08-25 2020-06-14 Five Prime Therapeutics Inc Anticuerpos de b7-h4 y métodos para usarlos
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
CN117865839A (zh) 2017-08-31 2024-04-12 第一三共株式会社 制备抗体-药物缀合物的新方法
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
IL301636B1 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
CN111954679A (zh) 2017-10-03 2020-11-17 朱诺治疗学股份有限公司 Hpv特异性结合分子
TW201927336A (zh) 2017-10-05 2019-07-16 日商第一三共股份有限公司 細胞毒性ｔ細胞耗竭用組成物
US11912754B2 (en) 2017-10-12 2024-02-27 Immunowake Inc. VEGFR-antibody light chain fusion protein
AU2018358067A1 (en) 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
AU2018359967A1 (en) 2017-11-06 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for cancer
AU2018363922A1 (en) 2017-11-08 2020-05-28 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to CD40 and EpCAM
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN111615520A (zh) 2017-12-01 2020-09-01 辉瑞大药厂 抗cxcr5抗体及其组合物和用途
KR20200096531A (ko) 2017-12-12 2020-08-12 쿄와 기린 가부시키가이샤 항bmp10 항체 및 해당 항체를 유효 성분으로 하는, 고혈압 및 고혈압성 질환에 대한 치료제
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法
CN111655718A (zh) 2017-12-19 2020-09-11 Xencor股份有限公司 经过工程化的il-2 fc融合蛋白
TW201929907A (zh) 2017-12-22 2019-08-01 美商建南德克公司 Pilra結合劑用於治療疾病之用途
EP4219559A3 (en) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
CA3078849A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1
CN111699198B (zh) 2017-12-28 2023-09-05 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
EP3724223A1 (en) 2018-01-02 2020-10-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
AU2019205090A1 (en) 2018-01-05 2020-08-06 Ac Immune Sa Misfolded TDP-43 binding molecules
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
WO2019143636A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
MX2020007018A (es) 2018-01-26 2020-09-07 Genentech Inc Proteinas de fusion fc il-22 y metodos de uso.
PL3743088T3 (pl) 2018-01-26 2023-03-20 F. Hoffmann-La Roche Ag Kompozycje i sposoby stosowania il-22 fc
CA3081125A1 (en) 2018-02-01 2019-08-08 Innovent Biologics (Suzhou) Co., Ltd. Fully humanized anti-b cell maturation antigen (bcma) single-chain antibody and use thereof
JP7475275B2 (ja) 2018-02-08 2024-04-26 ジェネンテック， インコーポレイテッド 二重特異性抗原結合分子及びその使用方法
CA3226165A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
EP3752530A1 (en) 2018-02-14 2020-12-23 ABBA Therapeutics AG Anti-human pd-l2 antibodies
AU2019226034A1 (en) 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
AU2019226085A1 (en) 2018-02-21 2020-09-17 Genentech, Inc. Dosing for treatment with IL-22 Fc fusion proteins
MA51903A (fr) 2018-02-21 2021-05-26 Five Prime Therapeutics Inc Formulations d'anticorps b7-h4
WO2019165075A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody dosing regimens
CN111836831A (zh) 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
SG11202008105RA (en) 2018-03-02 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
KR20200128017A (ko) 2018-03-05 2020-11-11 각코우호우징 사이타마이카다이가쿠 이소성 골화의 치료 또는 예방을 위한 의약 조성물
EP3765522A4 (en) 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODIES
JP7377590B2 (ja) 2018-03-14 2023-11-10 ノビミューン エスアー 抗ｃｄ３イプシロン抗体およびそれを使用する方法
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
TW202413402A (zh) 2018-03-15 2024-04-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體之用途
EP3774917A4 (en) 2018-03-30 2022-01-19 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3773908A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
CN110373374B (zh) * 2018-04-12 2023-07-07 上海颢哲信息科技有限公司 一种降低抗体核心岩藻糖基化的方法和组合物
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
SG11202010601VA (en) 2018-05-03 2020-11-27 Genmab Bv Antibody variant combinations and uses thereof
SG11202011243XA (en) 2018-05-28 2020-12-30 Daiichi Sankyo Co Ltd Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
AU2019279206A1 (en) 2018-05-31 2020-12-03 Daiichi Sankyo Company, Limited Anti-human TLR7 antibody
MX2020012613A (es) 2018-06-01 2021-04-13 Tayu Huaxia Biotech Medical Group Co Ltd Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
EP3805400A4 (en) 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule showing changed half-life in cytoplasm
US12048296B2 (en) 2018-06-07 2024-07-30 Korea Research Institute Of Bioscience And Biotechnology Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom
EP3806904A4 (en) 2018-06-18 2022-04-27 Eureka Therapeutics, Inc. PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED CONSTRUCTS AND USES THEREOF
WO2019246557A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
JP7397444B2 (ja) 2018-06-26 2023-12-13 協和キリン株式会社 コンドロイチン硫酸プロテオグリカン－５に結合する抗体
WO2020004492A1 (ja) 2018-06-26 2020-01-02 協和キリン株式会社 Ｃｅｌｌ Ａｄｈｅｓｉｏｎ Ｍｏｌｅｃｕｌｅ３に結合する抗体
CN112584859A (zh) 2018-07-02 2021-03-30 美国安进公司 抗steap1抗原结合蛋白
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
MX2020013631A (es) 2018-07-13 2021-03-25 Genmab As Variantes de anticuerpo grupo de diferenciacion (cd38) y usos de las mismas.
MA53123A (fr) 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
CN112839644A (zh) 2018-07-18 2021-05-25 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、抗代谢物和铂剂治疗肺癌的方法
WO2020018879A1 (en) 2018-07-20 2020-01-23 Surface Oncology, Inc. Anti-cd112r compositions and methods
BR112021001194A2 (pt) 2018-07-25 2021-04-27 Daiichi Sankyo Company, Limited métodos para produzir um conjugado anticorpo-fármaco e para produzir uma composição farmacêutica
US20210290777A1 (en) 2018-07-31 2021-09-23 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
CA3106829A1 (en) 2018-08-03 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
CA3108754A1 (en) 2018-08-06 2020-02-13 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor
MA50586A (fr) 2018-08-09 2020-09-16 Regeneron Pharma Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal
US20210324099A1 (en) 2018-08-10 2021-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-cd137 antigen-binding molecule and utilization thereof
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
TW202016317A (zh) 2018-08-23 2020-05-01 日商第一三共股份有限公司 抗體藥物結合物之感受性標記
EP3818149A4 (en) * 2018-08-29 2022-03-23 United Biopharma Inc AFUCOSYLATED ANTIBODIES AND THEIR PRODUCTION
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3111458A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
US20220098613A1 (en) 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
CA3111401A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
BR112021005246A2 (pt) 2018-09-20 2021-06-15 Daiichi Sankyo Company, Limited agente terapêutico, e, método de tratamento para câncer
EP3854875A4 (en) 2018-09-21 2022-07-06 National University Corporation Tokyo Medical and Dental University HUMAN MONOCLONAL ANTIBODY BINDING SPECIFICALLY TO HUMAN HMGB1, AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE CONTAINING SUCH HUMAN MONOCLONAL ANTIBODY
MX2021003213A (es) 2018-09-21 2021-05-12 Genentech Inc Metodos de diagnostico para cancer de mama triple negativo.
WO2020067541A1 (ja) 2018-09-28 2020-04-02 協和キリン株式会社 抗体組成物
CN113195523A (zh) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12异源二聚体Fc融合蛋白
US20220010020A1 (en) 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
MX2021004226A (es) 2018-10-15 2021-07-15 Five Prime Therapeutics Inc Terapia combinada contra el cáncer.
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
AU2019361983A1 (en) 2018-10-18 2021-05-20 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
EP3882349A4 (en) 2018-11-14 2023-04-05 Daiichi Sankyo Company, Limited (ANTI-CDH6 ANTIBODY)-(PYRROLOBENZODIAZEPINE DERIVATIVE) CONJUGATE
JP2022513050A (ja) 2018-11-16 2022-02-07 メモリアル スローン ケタリング キャンサー センター ムチン－１６に対する抗体およびそれを使用する方法
JP2022511502A (ja) 2018-12-05 2022-01-31 ジェネンテック， インコーポレイテッド がんの免疫療法のための診断方法及び診断用組成物
CA3119798A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
AU2019396895A1 (en) 2018-12-11 2021-07-08 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with PARP inhibitor
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
TW202035442A (zh) 2018-12-20 2020-10-01 美商建南德克公司 經修飾之抗體Fc及其使用方法
US20220089694A1 (en) 2018-12-20 2022-03-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
EP3898673A1 (en) 2018-12-21 2021-10-27 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
BR112021011431A2 (pt) 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
TW202039581A (zh) 2018-12-28 2020-11-01 日商協和麒麟股份有限公司 與TfR結合之雙專一性抗體
CN113272327A (zh) 2018-12-30 2021-08-17 豪夫迈·罗氏有限公司 抗兔cd19抗体及其使用方法
CA3124837A1 (en) 2019-01-14 2020-07-23 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
EP3917570A1 (en) 2019-01-29 2021-12-08 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR20210133237A (ko) 2019-02-27 2021-11-05 제넨테크, 인크. 항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
JP2022523946A (ja) 2019-03-01 2022-04-27 ゼンコア インコーポレイテッド Ｅｎｐｐ３およびｃｄ３に結合するヘテロ二量体抗体
KR20210138588A (ko) 2019-03-08 2021-11-19 제넨테크, 인크. 세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
JP2022524074A (ja) 2019-03-14 2022-04-27 ジェネンテック， インコーポレイテッド 抗ＨＥＲ２ ＭＡＢと組み合わせたＨＥＲ２ｘＣＤ３二重特異性抗体によるがんの処置
JPWO2020189748A1 (pt) 2019-03-19 2020-09-24
JPWO2020196474A1 (pt) 2019-03-25 2020-10-01
US20220177601A1 (en) 2019-03-25 2022-06-09 Daiichi Sankyo Company, Limited Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
JP7522097B2 (ja) 2019-03-27 2024-07-24 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲートとｐａｒｐ阻害剤の組み合わせ
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
BR112021020867A2 (pt) 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
US20220227853A1 (en) 2019-05-03 2022-07-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2020226986A2 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
TW202108178A (zh) 2019-05-14 2021-03-01 美商建南德克公司 使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
KR20220008820A (ko) 2019-05-15 2022-01-21 쿄와 기린 가부시키가이샤 Cd40과 fap에 결합하는 이중 특이적 항체
JP7502281B2 (ja) 2019-05-15 2024-06-18 協和キリン株式会社 Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
SG11202112453TA (en) 2019-05-23 2021-12-30 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
KR20220015445A (ko) 2019-05-29 2022-02-08 다이이찌 산쿄 가부시키가이샤 항체-약물 접합체의 투약
CN114269783B (zh) 2019-07-02 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) 结合egfrviii的单克隆抗体及其应用
US20220267453A1 (en) 2019-07-26 2022-08-25 Saitama Medical University Antibody recognizing extracellular region of alk2/acvr1
TWI832183B (zh) 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
EP4028054A1 (en) 2019-09-12 2022-07-20 Genentech, Inc. Compositions and methods of treating lupus nephritis
AU2020346580A1 (en) 2019-09-13 2022-03-31 Kyowa Kirin Co., Ltd. DcR3 variant
US20220348687A1 (en) 2019-09-20 2022-11-03 Genentech, Inc. Dosing for anti-tryptase antibodies
WO2021062085A1 (en) 2019-09-27 2021-04-01 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN118557750A (zh) 2019-10-18 2024-08-30 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
US20240190961A1 (en) 2019-10-25 2024-06-13 Daiichi Sankyo Company, Limited Combination of anti-garp antibody and immunomodulator
JP2022553803A (ja) 2019-11-06 2022-12-26 ジェネンテック， インコーポレイテッド 血液がんの処置のための診断方法及び治療方法
EP4069741A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
CN115335399A (zh) 2019-12-06 2022-11-11 朱诺治疗学股份有限公司 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
CA3163950A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
WO2021127414A1 (en) 2019-12-20 2021-06-24 Bristol-Myers Squibb Company Use of fucosylation inhibitor for producing afucosylated antibody
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
JP7373588B2 (ja) 2019-12-27 2023-11-02 中外製薬株式会社 抗ｃｔｌａ－４抗体およびその使用
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
JPWO2021145432A1 (pt) 2020-01-15 2021-07-22
CA3168209A1 (en) 2020-01-15 2021-07-22 Osaka University Prophylactic or therapeutic agent for dementia
JP2023510397A (ja) 2020-01-16 2023-03-13 ジェンマブ エー／エス Ｃｄ３８抗体の製剤およびその使用
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021155295A1 (en) 2020-01-31 2021-08-05 The Cleveland Clinic Foundation Anti-müllerian hormone receptor 2 antibodies and methods of use
IL294859A (en) 2020-01-31 2022-09-01 Genentech Inc Methods for induction of neoepitope-specific t cells with spindle-binding antagonist 1-pd and RNA vaccine
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
TW202140561A (zh) 2020-02-14 2021-11-01 日商協和麒麟股份有限公司 與cd3結合之雙特異性抗體
US20230348568A1 (en) 2020-02-20 2023-11-02 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus monoclonal antibodies and uses thereof
KR20220148209A (ko) 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물 및 그 용도
AU2021228078A1 (en) 2020-02-28 2022-09-22 Shanghai Henlius Biotech, Inc. Anti-CD137 constructs, multispecific antibody and uses thereof
CN115605507A (zh) 2020-03-13 2023-01-13 基因泰克公司（Us） 抗白介素-33抗体及其用途
CR20220524A (es) 2020-03-19 2022-12-02 Genentech Inc Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso
US11999787B2 (en) 2020-03-24 2024-06-04 Genentech, Inc. Tie2-binding agents and methods of use
WO2021200857A1 (ja) 2020-03-30 2021-10-07 国立大学法人三重大学 二重特異的抗体
US20240261424A1 (en) 2020-03-30 2024-08-08 National Cancer Center Antibody drug conjugate
WO2021201236A1 (ja) 2020-04-01 2021-10-07 協和キリン株式会社 抗体組成物
JP2023520515A (ja) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド がんに対する治療方法及び診断方法
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
KR20230005903A (ko) 2020-04-24 2023-01-10 제넨테크, 인크. 항-CD79b 면역접합체를 사용하는 방법
AU2021262744A1 (en) 2020-04-27 2022-10-06 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
MX2022013768A (es) 2020-05-03 2023-01-05 Levena Suzhou Biopharma Co Ltd Conjugados anticuerpo-fármaco (adc) que comprenden un anticuerpo anti-trop-2, composiciones que comprenden dichos adc, así como métodos para fabricar y utilizar los mismos.
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
MX2022014422A (es) 2020-05-17 2022-12-07 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y metodos de seleccion y uso de los mismos.
WO2021238886A1 (en) 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
JP2023528375A (ja) 2020-05-29 2023-07-04 ２３アンドミー・インコーポレイテッド 抗ｃｄ２００ｒ１抗体及びその使用方法
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
TW202210515A (zh) 2020-06-02 2022-03-16 美商當康生物科技有限公司 抗ｃｄ３９之構築體及其用途
CN115698719A (zh) 2020-06-12 2023-02-03 基因泰克公司 用于癌症免疫疗法的方法和组合物
KR20230025691A (ko) 2020-06-16 2023-02-22 제넨테크, 인크. 삼중 음성 유방암을 치료하기 위한 방법과 조성물
EP4168118A1 (en) 2020-06-18 2023-04-26 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
EP4168443A1 (en) 2020-06-22 2023-04-26 Almirall S.A. Anti-il-36 antibodies and methods of use thereof
CN116670285A (zh) 2020-06-23 2023-08-29 江苏康缘药业股份有限公司 抗cd38抗体及其用途
US20230233540A1 (en) 2020-06-24 2023-07-27 Astrazeneca Uk Limited Combination of antibody-drug conjugate and cdk9 inhibitor
CA3183867A1 (en) 2020-06-24 2021-12-30 Jerome Thomas Mettetal Ii Combination of antibody-drug conjugate and atr inhibitor
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2021260580A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
US20230256092A1 (en) 2020-06-30 2023-08-17 Shionogi & Co., Ltd. Combined use of anti-ccr8 antibody and chemotherapeutic agent
WO2022014698A1 (ja) 2020-07-17 2022-01-20 第一三共株式会社 抗体－薬物コンジュゲートの製造方法
CN115884794A (zh) 2020-07-20 2023-03-31 第一三共株式会社 抗her2抗体药物缀合物与her二聚化抑制剂的组合
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
KR20230133832A (ko) 2020-07-29 2023-09-19 다이내믹큐어 바이오테크놀로지 엘엘씨 항-cd93 구축물 및 그의 용도
EP4189121A1 (en) 2020-08-03 2023-06-07 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
JP2023536326A (ja) 2020-08-05 2023-08-24 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
CR20230119A (es) 2020-08-07 2023-05-16 Genentech Inc Proteínas de fusión del ligando para flt3 y métodos de uso
IL300257A (en) 2020-08-10 2023-03-01 Astrazeneca Uk Ltd SARS-COV-2 antibodies for the treatment and prevention of COVID-19
WO2022034228A1 (en) 2020-08-14 2022-02-17 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2022040482A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
WO2022054009A2 (en) 2020-09-12 2022-03-17 Astrazeneca Uk Limited A scoring method for an anti-her2 antibody-drug conjugate therapy
AU2021341526A1 (en) 2020-09-14 2023-04-27 Ichnos Sciences SA Antibodies that bind to il1rap and uses thereof
CA3193952A1 (en) 2020-10-05 2022-04-14 Bernard Martin Fine Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2021356762A1 (en) 2020-10-09 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2022084400A1 (en) 2020-10-20 2022-04-28 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
JP2023548064A (ja) 2020-11-04 2023-11-15 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び抗ｃｄ７９ｂ抗体薬物コンジュゲートによる処置のための投与
US20220162329A1 (en) 2020-11-04 2022-05-26 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2021374590A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
IL302812A (en) 2020-11-11 2023-07-01 Daiichi Sankyo Co Ltd Antibody-drug conjugate combinations with anti-SIRP alpha antibody
EP4245322A1 (en) 2020-11-12 2023-09-20 Daiichi Sankyo Company, Limited Treatment for mesothelioma through administration of anti-b7-h3 antibody-drug conjugate
US20240002531A1 (en) 2020-11-30 2024-01-04 Ono Pharmaceutical Co., Ltd. Her2 targeting agent
EP4260872A4 (en) 2020-12-09 2024-11-13 Univ Nat Corp Tokyo Medical & Dental AGENT FOR PREVENTION OR TREATMENT OF FRONTO-TEMPORAL LOBAR DEGENERATION
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
JP2024503657A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
KR20230147099A (ko) 2021-01-28 2023-10-20 백신벤트 게엠베하 B 세포 매개 면역 반응을 조절하기 위한 방법 및 수단(method and means for modulating b-cell mediated immune responses)
EP4291226A1 (en) 2021-02-09 2023-12-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Antibodies targeting the spike protein of coronaviruses
US20240117019A1 (en) 2021-02-09 2024-04-11 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
JP2024506200A (ja) 2021-02-15 2024-02-09 武田薬品工業株式会社 細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
JP2024509169A (ja) 2021-03-03 2024-02-29 ソレント・セラピューティクス・インコーポレイテッド 抗ｂｃｍａ抗体を含む抗体－薬物コンジュゲート
JP2024509191A (ja) 2021-03-05 2024-02-29 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａ構築物およびその使用
MX2023010499A (es) 2021-03-09 2023-09-18 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cldn6.
AU2022232951A1 (en) 2021-03-10 2023-10-19 Immunowake Inc. Immunomodulatory molecules and uses thereof
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
EP4454652A2 (en) 2021-03-15 2024-10-30 F. Hoffmann-La Roche AG Compositions and methods for treating lupus nephritis
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
US20240150466A1 (en) 2021-03-25 2024-05-09 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
KR20230162597A (ko) 2021-03-29 2023-11-28 다이이찌 산쿄 가부시키가이샤 안정적인 다중 특이성 분자 및 그 이용
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
MX2023012408A (es) 2021-04-30 2023-10-31 Hoffmann La Roche Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.
IL308351A (en) 2021-05-12 2024-01-01 Genentech Inc Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
TW202306993A (zh) 2021-05-14 2023-02-16 美商建南德克公司 Ｔｒｅｍ２之促效劑
US20240270853A1 (en) 2021-06-04 2024-08-15 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
WO2022258600A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
KR102690145B1 (ko) 2021-06-25 2024-07-30 추가이 세이야쿠 가부시키가이샤 항ctla-4 항체의 사용
AU2022299846B2 (en) 2021-06-25 2024-08-15 Chugai Seiyaku Kabushiki Kaisha Anti–ctla-4 antibody
TW202317633A (zh) 2021-07-08 2023-05-01 美商舒泰神（加州）生物科技有限公司 特異性識別ｔｎｆｒ２的抗體及其用途
WO2023284714A1 (zh) 2021-07-14 2023-01-19 舒泰神（北京）生物制药股份有限公司 特异性识别cd40的抗体及其应用
EP4373576A1 (en) 2021-07-22 2024-05-29 Genentech, Inc. Brain targeting compositions and methods of use thereof
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN117897409A (zh) 2021-08-13 2024-04-16 基因泰克公司 抗类胰蛋白酶抗体的给药
CN117858905A (zh) 2021-08-19 2024-04-09 豪夫迈·罗氏有限公司 多价抗变体fc区抗体及使用方法
MX2024002349A (es) 2021-08-26 2024-03-13 Kyowa Kirin Co Ltd Anticuerpo biespecifico que se une a cd116 y cd131.
WO2023028591A1 (en) 2021-08-27 2023-03-02 Genentech, Inc. Methods of treating tau pathologies
TW202325727A (zh) 2021-08-30 2023-07-01 美商建南德克公司 抗聚泛素多特異性抗體
IL311141A (en) 2021-09-06 2024-04-01 Genmab As Antibodies capable of binding to CD27, their variants and uses thereof
MX2024003277A (es) 2021-09-15 2024-04-04 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia.
AU2022345251A1 (en) 2021-09-17 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
TW202323810A (zh) 2021-10-08 2023-06-16 日商中外製藥股份有限公司 預填充式注射器製劑的調製方法
CA3235358A1 (en) 2021-10-18 2023-04-27 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
WO2023081818A1 (en) 2021-11-05 2023-05-11 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal antibodies against carcinoembryonic antigens, and their uses
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
MX2024005680A (es) 2021-11-16 2024-05-30 Genentech Inc Metodos y composiciones para tratar lupus eritematoso sistemico (sle) con mosunetuzumab.
TW202334202A (zh) 2021-11-16 2023-09-01 瑞士商Ａｃ免疫有限公司 用於治療和診斷的新分子
CN118414173A (zh) 2021-11-18 2024-07-30 阿斯利康(英国)有限公司 抗体-药物缀合物和parp1选择性抑制剂的组合
JPWO2023100829A1 (pt) 2021-11-30 2023-06-08
EP4445911A1 (en) 2021-12-06 2024-10-16 Beijing SoloBio Genetechnology Co., Ltd. Bispecific antibody that specifically binds to klebsiella pneumoniae o2 and o1 antigens, and composition
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
WO2023109901A1 (en) 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
TW202333800A (zh) 2021-12-28 2023-09-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及rasg12c抑制劑之組合
KR20240130087A (ko) 2021-12-28 2024-08-28 아스트라제네카 유케이 리미티드 항체-약물 접합체와 atr 저해제의 조합
IL314129A (en) 2022-01-07 2024-09-01 Johnson & Johnson Entpr Innovation Inc Materials and methods of IL-1BETA binding proteins
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy
MX2024009817A (es) 2022-02-09 2024-08-19 Nat Inst Biomedical Innovation Health & Nutrition Anticuerpo o fragmento del mismo que se une a fcrl1.
IL314707A (en) 2022-02-09 2024-10-01 Daiichi Sankyo Co Ltd Environmentally reactive masked antibody and its use
AU2023219176A1 (en) 2022-02-10 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
MX2024010003A (es) 2022-02-18 2024-09-30 Rakuten Medical Inc Moléculas de anticuerpo anti-ligando 1 de muerte programada (pd-l1), polinucleótidos que las codifican y métodos de uso.
WO2023171009A1 (ja) 2022-03-09 2023-09-14 株式会社Cured Ｅｖａ１タンパク質に結合する、ヒト化抗体又はその機能的断片、抗体薬物複合体及びキメラ抗原受容体
WO2023173026A1 (en) 2022-03-10 2023-09-14 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
CN118891525A (zh) 2022-03-16 2024-11-01 阿斯利康(英国)有限公司 用于抗trop2抗体-药物缀合物疗法的评分方法
TW202400232A (zh) 2022-03-16 2024-01-01 日商第一三共股份有限公司 多特異性分子與免疫檢查點抑制劑之組合
TW202346365A (zh) 2022-03-23 2023-12-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療
AU2023240941A1 (en) 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use
AU2023241824A1 (en) 2022-03-26 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to hiv-1 env and their use
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
IL315770A (en) 2022-04-01 2024-11-01 Genentech Inc Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
TW202408562A (zh) 2022-04-13 2024-03-01 美商建南德克公司 治療性蛋白質之醫藥組成物及使用方法
IL315887A (en) 2022-04-13 2024-11-01 F Hoffmann La Roche Ag Pharmaceutical preparations of anti-CD20/anti-CD3 bispecific antibodies and methods of use
AU2023258146A1 (en) 2022-04-20 2024-09-05 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
AU2023262308A1 (en) 2022-04-27 2024-10-03 Astrazeneca Uk Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023218378A1 (en) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2023237706A2 (en) 2022-06-08 2023-12-14 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof
TW202417042A (zh) 2022-07-13 2024-05-01 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
TW202417503A (zh) 2022-07-19 2024-05-01 美商舒泰神（加州）生物科技有限公司 特異性識別ｂ和ｔ淋巴細胞衰減器（ｂｔｌａ）的抗體及其應用
TW202413433A (zh) 2022-07-19 2024-04-01 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024028731A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
WO2024028732A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors
TW202417034A (zh) 2022-08-19 2024-05-01 大陸商億一生物醫藥開發（上海）有限公司 包含ｇ—ｃｓｆ之調配物及其用途
WO2024044779A2 (en) 2022-08-26 2024-02-29 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
WO2024097741A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
WO2024102734A1 (en) 2022-11-08 2024-05-16 Genentech, Inc. Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100200A1 (en) 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
US20240226313A1 (en) 2022-11-17 2024-07-11 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
WO2024116094A1 (en) 2022-11-30 2024-06-06 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugates and dnmt inhibitors
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
CN116200329B (zh) * 2023-02-22 2023-08-29 洛阳赛奥生物工程技术有限公司 一种无血清昆虫培养基及应用
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024212827A1 (en) 2023-04-12 2024-10-17 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5613352A (en) 1979-07-02 1981-02-09 Tokan Kogyo Co Ltd Easily openable container
DE3382839D1 (de) 1983-01-13 2004-12-23 Max Planck Gesellschaft Nichtonkogenisches Ti-Plasmidvektorsystem und für das Einschleusen expressionsfähiger Gene in Pflanzengenomen verwendbare rekombinante DNA-Moleküle
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
JPS60123857A (ja) 1983-12-09 1985-07-02 Konishiroku Photo Ind Co Ltd 画像形成方法
DE3588230D1 (de) 1984-05-11 2001-09-13 Syngenta Participations Ag Transformation von Pflanzenerbgut
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
IL84459A (en) 1986-12-05 1993-07-08 Agracetus Apparatus and method for the injection of carrier particles carrying genetic material into living cells
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
JP3131322B2 (ja) 1991-12-17 2001-01-31 協和醗酵工業株式会社 新規α２→３シアリルトランスフェラーゼ
EP1983056A1 (en) 1992-07-07 2008-10-22 Japan Tobacco Inc. Method for transforming monocotyledons
JP3154564B2 (ja) * 1992-09-07 2001-04-09 科学技術振興事業団 モノクローナル抗体の改変方法
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6054304A (en) * 1996-01-24 2000-04-25 Toyo Boseki Kabushiki Kaisha α1-6 fucosyltransferase
EP0904101B1 (en) 1996-04-10 2006-01-18 Neose Technologies, Inc. Nucleic acids encoding gdp-fucose pyrophosphorylase
US5728568A (en) * 1996-11-22 1998-03-17 Genetics Institute, Inc. Human GDP-mannose 4,6 dehydratase
JP4550947B2 (ja) * 1997-03-19 2010-09-22 協和発酵キリン株式会社 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
JP3991294B2 (ja) 1998-05-06 2007-10-17 株式会社ヴァレオサーマルシステムズ 自動車用空気調和装置のファンユニット
US20020012979A1 (en) * 1998-06-08 2002-01-31 Alan Berry Vitamin c production in microorganisms and plants
EP2270150B2 (en) * 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2000308526A (ja) 1999-04-28 2000-11-07 Yoshihiro Inomura 鐙型ブラシ
SI1270595T1 (sl) 2000-03-03 2008-12-31 Kyowa Hakko Kogyo Kk Protitelo proti CCR4 in njegov fragment
JP5623683B2 (ja) * 2000-03-22 2014-11-12 フィトン ホールディングス，リミティド ライアビリティ カンパニー 動物型糖鎖付加機能をもつ植物細胞
CN1894406A (zh) * 2000-10-06 2007-01-10 协和发酵工业株式会社 产生抗体组合物的细胞
AU2004279736A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to ganglioside GM2
JP6109648B2 (ja) * 2013-05-29 2017-04-05 株式会社ぐるなび 鉄道を利用した商品販売支援システム

Also Published As

Publication number Publication date
JP6010147B2 (ja) 2016-10-19
JP6523404B2 (ja) 2019-05-29
JP4740931B2 (ja) 2011-08-03
EA200300443A1 (ru) 2003-10-30
ES2651952T3 (es) 2018-01-30
EA013563B1 (ru) 2010-06-30
JPWO2002031140A1 (ja) 2004-02-19
AU9419801A (en) 2002-04-22
EA200600469A1 (ru) 2006-08-25
CA2785941A1 (en) 2002-04-18
JP5384601B2 (ja) 2014-01-08
JP5770783B2 (ja) 2015-08-26
ES2639222T3 (es) 2017-10-25
CA2424602A1 (en) 2003-04-02
EP2314685A1 (en) 2011-04-27
WO2002031140A1 (fr) 2002-04-18
HUP0402066A3 (en) 2012-09-28
JP4290423B2 (ja) 2009-07-08
JP2015131807A (ja) 2015-07-23
EP2314686A1 (en) 2011-04-27
CN103333860A (zh) 2013-10-02
JP2018078890A (ja) 2018-05-24
JP2009142288A (ja) 2009-07-02
EP1331266A1 (en) 2003-07-30
JP2008113663A (ja) 2008-05-22
JP2012087131A (ja) 2012-05-10
CN102311986A (zh) 2012-01-11
DK2314686T4 (da) 2023-08-21
ES2639222T5 (es) 2023-11-24
CA2424602C (en) 2012-09-18
AU2001294198B2 (en) 2007-11-29
ES2620359T3 (es) 2017-06-28
PL362520A1 (en) 2004-11-02
EP2314686B2 (en) 2023-06-21
JP4741011B2 (ja) 2011-08-03
HUP0402066A2 (hu) 2005-01-28
JP6270930B2 (ja) 2018-01-31
KR100877676B1 (ko) 2009-01-09
CN103333860B (zh) 2015-07-08
AU2001294198C1 (en) 2019-04-04
EP1331266B1 (en) 2017-01-04
CA2953239A1 (en) 2002-04-18
EA013224B1 (ru) 2010-04-30
DK2314686T3 (en) 2017-09-11
PL218428B1 (pl) 2014-12-31
EP2314685B1 (en) 2017-09-20
JP2016185163A (ja) 2016-10-27
CN102311986B (zh) 2015-08-19
EP1331266A4 (en) 2005-07-13
JP2013231032A (ja) 2013-11-14
JP2012085655A (ja) 2012-05-10
JP5815641B2 (ja) 2015-11-17
JP2014043455A (ja) 2014-03-13
HUS2000035I1 (hu) 2022-11-28
EP3690043A1 (en) 2020-08-05
CA2785941C (en) 2017-01-10
JP2012075441A (ja) 2012-04-19
JP5547754B2 (ja) 2014-07-16
MXPA03002974A (es) 2004-05-05
JP2011092203A (ja) 2011-05-12
JP5301525B2 (ja) 2013-09-25
AU2001294198B9 (en) 2008-08-07
HU231090B1 (hu) 2020-07-28
KR20030081312A (ko) 2003-10-17
EP2314686B1 (en) 2017-07-05
EP3263702A1 (en) 2018-01-03
CN1894406A (zh) 2007-01-10
JP5384677B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
BR0114475A (pt) Célula para a produção de composição de anticorpo
BR9713521A (pt)
ATE464373T1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
BR0310088A (pt) Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s)
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
PT96068A (pt) Processo para a producao de proteina biologicamente activa
DE60141043D1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
ATE465257T1 (de) Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
BRPI0411112A (pt) proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
BR0017026A (pt) Lipeptìdeos como agentes antibacterianos
ES2068907T3 (es) Secuencias de nucleotidos que codifican una proteina con actividad ureasica.
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
ATE234108T1 (de) Therapeutikum zur unterdrückung von schnarchgeräuschen
BR9710303A (pt) Processos para altera-Æo de crescimento de cabelo e pigmenta-Æo de cabelo por apoptose nas papilas foliculares e composi-{es para os mesmos
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
ATE212059T1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
BR9811094A (pt) Agente terapêutico para tumores linfáticos
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
HUP9901411A2 (hu) Aktív sündisznófehérje konjugátum, eljárás ennek előállítására és felhasználása
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: KYOWA KIRIN CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: KYOWA KIRIN CO., LTD. (JP)